News Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.5299 ^USD	-2.91%		-20.91%	+3.33%

May. 09	Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M	MT
Apr. 01	Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atara Biotherapeutics: Q1 Earnings Snapshot	May. 09	AQ
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M	May. 09	MT
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress	May. 09	BU
ATARA BIOTHERAPEUTICS, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)	May. 06	AQ
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	May. 03	BU
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05	BU
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	Apr. 01	MT
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	Mar. 29	CI
Atara Biotherapeutics: Q4 Earnings Snapshot	Mar. 28	AQ
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress	Mar. 28	BU
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M	Mar. 28	MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy	Feb. 29	MT
Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application	Feb. 29	DJ
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy	Feb. 29	BU
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference	Feb. 28	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Summary

Filters